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ticular, homozygous autosomal dominant hypercholesterol-
aemia, an orphan disease caused by mutations in the LDL 
receptor, apolipoprotein B (APOB), or PCSK9, is character-
ised by elevated LDL-C levels [8].
At the same time as the approval of evolocumab, the US 
Food and Drug Administration (FDA) approved another 
PCSK9 inhibitor, alirocumab (Praluent) produced by Sanofi 
and Regeneron. Alirocumab was approved for people with 
an inherited condition that causes very high LDL-C levels, 
as well as for the millions of individuals who have sustained 
a myocardial infarction, cerebrovascular accident or other 
types of cardiovascular disease and whose LDL-C is higher 
than desirable [9]. Monotherapy with alirocumab demon-
strated significantly greater LDL-C lowering versus ezeti-
mibe after 24 weeks with the lower 75 mg dose sufficient 
to provide ≥ 50 % LDL-C reduction in the majority of the 
patients [10]. As PCSK9 is an attractive target for lowering 
plasma LDL-C with potential plaque-stabilising features, 
the ODYSSEY OUTCOMES trial was recently initiated to 
evaluate the efficacy of alirocumab in patients with cardio-
vascular disease [11]. This Phase 3 study will randomise 
approximately 18,000 patients to receive biweekly subcu-
taneous injections of alirocumab (75–150 mg) or matching 
placebo beginning 1 to 12 months after an index hospitali-
sation for acute myocardial infarction or unstable angina. 
ODYSSEY OUTCOMES will therefore determine whether 
the addition of the PCSK9 antibody alirocumab to intensive 
statin therapy reduces cardiovascular morbidity and mortal-
ity in patients with acute coronary syndromes [12]. As part of 
the overall ODYSSEY program, the European Heart Journal 
published the ODYSSEY COMBO II trial in May 2015, with 
the aim to compare the efficacy and safety of alirocumab, 
versus ezetimibe, as add-on therapy to maximally toler-
ated statin therapy in high cardiovascular risk patients with 
inadequately controlled hypercholesterolaemia [13]. In 720 
Statins are the current standard treatment of patients with hyper-
cholesterolaemia. These drugs have been shown to be very 
effective in reducing the incidence of cardiovascular disease 
[1, 2]. Nevertheless, a substantial number of patients do not 
achieve their target low-density lipid protein cholesterol (LDL-
C) levels. Consequently, new treatment options are required to 
decrease LDL-C levels beyond those currently achieved.
In July 2015 it was reported that Amgen Inc.’s choles-
terol medication, evolocumab (Repatha), has received regu-
latory approval from the European Commission, making it 
the first regulatory clearance for a new class of powerful 
cholesterol-lowering drugs. Evolocumab is an inhibitor of 
PCSK9, which stands for protease proprotein convertase 
subtilisin/kexin 9 (PCSK9), an enzyme shown to down-reg-
ulate LDL-C receptor protein levels. Already more than 10 
years ago, PCSK9 emerged as a validated target for lowering 
plasma LDL-C levels [3, 4]. PCSK9 inhibitors are designed 
to treat patients with persistently high LDL-C levels despite 
optimal use of statins. The drug has to be injected subcu-
taneously once every two weeks. The European Commis-
sion cleared evolocumab for patients with hazardously high 
cholesterol levels including those with inherited conditions. 
In the largest monotherapy trial using a PCSK9 inhibitor 
to date, evolocumab yielded significant LDL-C reductions 
compared with placebo or ezetimibe and was well toler-
ated in patients with hypercholesterolaemia [5]. Familial 
hypercholesterolaemia is an autosomal dominant genetic 
disorder, associated with elevated levels of LDL-C, which 
can lead to premature cardiovascular disease [6, 7]. In par-
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patients it was shown that alirocumab achieved significantly 
greater reductions in LDL-C compared with ezetimibe, 
with a similar safety profile. The findings of the ODYSSEY 
COMBO II trial add to the evidence of alirocumab as a safe 
and efficacious option for patients whose LDL-C is insuf-
ficiently controlled under maximally dosed statin therapy, as 
is the case for an increasing number of high-risk patients.
The FDA is expected to have made a decision for evo-
locumab by the end of August 2015. Although PCSK9 
inhibitors appear a valuable new option in the treatment of 
patients with persistently high LDL-C levels, the approval 
of either cholesterol drug by the FDA and the European 
Commission will fuel the combat over the high price of 
treatment by PCSK9 inhibitors. It has been estimated that 
the new drugs would cost US$ 7,000 to $ 12,000 a year 
(6380–10,940 €), which is significantly more expensive 
than existing generic statin alternatives. More recent data 
even suggest that the medication’s list price is approxi-
mately US$ 14,600 annually (12,760 €). For that reason, it 
is currently recommended that physicians limit prescribing 
only to the very-high-risk, hard-to-treat groups.
Of crucial importance is that more data are needed to 
establish whether the next-generation drugs actually translate 
into less cardiovascular morbidity and mortality. As a result, 
the definitive long-term results of the clinical trials that are in 
progress, such as the ODYSSEY OUTCOMES trial and the 
OSLER trials, have to be awaited [12, 14]. At present, statins 
are available as low-cost generics, are well tolerated in most 
patients, and their effectiveness is supported by strong evi-
dence in a large spectrum of cardiovascular diseases [15–
18]. In the meantime, physicians are advised to follow the 
current guidelines, which recommend lifestyle change and, 
if needed, statins for most patients with or at risk of heart 
disease. Improving diet and optimising exercise remain the 
cornerstones of heart disease management and prevention.
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